About Actimo Labs

This startup provides in silico solutions for antibody safety and development, specializing in epitope mapping and off-target prediction. They offer predictive modeling services to identify binding sites and potential adverse effects of monoclonal antibodies (mAbs) during preclinical stages, leveraging computational biology in drug development.

```xml <problem> Traditional preclinical antibody development relies on time-consuming and costly tissue cross-reactivity screens, often delaying the identification of potential off-target effects and hindering efficient drug development. Accurately predicting antibody-antigen interactions and potential adverse effects early in the development process remains a significant challenge. </problem> <solution> Actimo Labs offers CRO 2.0, an AI-driven platform that provides in silico solutions for enhancing antibody safety and accelerating preclinical development. The platform leverages sequence and structure data to annotate antibodies, map binding sites on both the antibody and the antigen, and conduct similarity tests to rank the affinity of binding sites. Actimo Labs' predictive modeling services identify epitopes on the antigen and predict off-target sites, enabling clients to gain early insights into their monoclonal antibodies (mAbs) and reduce the risk of adverse side effects. By providing comprehensive antibody-antigen affinity reports, Actimo Labs helps strengthen intellectual property and improve drug safety profiles. </solution> <features> - AI-driven in silico modeling for antibody-antigen interaction analysis - Epitope mapping to identify paratopes on monoclonal antibodies (mAbs) - Off-target prediction to reduce the risk of adverse side effects - Comprehensive antibody-antigen affinity reports - Secure cloud hosting with encryption-grade security practices - User-owned data and IP with isolated computations </features> <target_audience> Actimo Labs primarily serves biotech companies, clinical researchers, and computational biologists involved in preclinical antibody development and seeking to accelerate their drug discovery process while improving safety profiles. </target_audience> ```

What does Actimo Labs do?

Where is Actimo Labs located?

Actimo Labs is based in Melbourne, Australia.

When was Actimo Labs founded?

Actimo Labs was founded in 2024.

Location

Melbourne, Australia

Founded

2024

Employees

4 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Actimo Labs

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

actimolabs.com 100+

Founded 2024 – Melbourne, Australia

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Traditional preclinical antibody development relies on time-consuming and costly tissue cross-reactivity screens, often delaying the identification of potential off-target effects and hindering efficient drug development. Accurately predicting antibody-antigen interactions and potential adverse effects early in the development process remains a significant challenge.

Solution

Actimo Labs offers CRO 2.0, an AI-driven platform that provides in silico solutions for enhancing antibody safety and accelerating preclinical development. The platform leverages sequence and structure data to annotate antibodies, map binding sites on both the antibody and the antigen, and conduct similarity tests to rank the affinity of binding sites. Actimo Labs' predictive modeling services identify epitopes on the antigen and predict off-target sites, enabling clients to gain early insights into their monoclonal antibodies (mAbs) and reduce the risk of adverse side effects. By providing comprehensive antibody-antigen affinity reports, Actimo Labs helps strengthen intellectual property and improve drug safety profiles.

Features

AI-driven in silico modeling for antibody-antigen interaction analysis

Epitope mapping to identify paratopes on monoclonal antibodies (mAbs)

Off-target prediction to reduce the risk of adverse side effects

Comprehensive antibody-antigen affinity reports

Secure cloud hosting with encryption-grade security practices

User-owned data and IP with isolated computations

Target Audience

Actimo Labs primarily serves biotech companies, clinical researchers, and computational biologists involved in preclinical antibody development and seeking to accelerate their drug discovery process while improving safety profiles.